Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (24,762)
  • Open Access

    ARTICLE

    Hsa-miR-214-3p inhibits breast cancer cell growth and improves the tumor immune microenvironment by downregulating B7H3

    YAN LU1,2,#, KANG WANG3,#, YUANHONG PENG3,4, MENG CHEN5, LIN ZHONG3,4, LUJI HUANG3,4, FU CHENG3,4, XINDAN SHENG4,6, XIN YANG4,6, MANZHAO OUYANG3,4, GEORGE A. CALIN5,*, ZHIWEI HE1,*

    Oncology Research, Vol.33, No.1, pp. 103-121, 2025, DOI:10.32604/or.2024.057472 - 20 December 2024

    Abstract Background: Immune checkpoint inhibitors play an important role in the treatment of solid tumors, but the currently used immune checkpoint inhibitors targeting programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), and cytotoxic T-lymphocyte antigen-4 (CTLA-4) show limited clinical efficacy in many breast cancers. B7H3 has been widely reported as an immunosuppressive molecule, but its immunological function in breast cancer patients remains unclear. Methods: We analyzed the expression of B7H3 in breast cancer samples using data from the Cancer Genome Atlas Program (TCGA) and the Gene Expression Omnibus (GEO) databases. MicroRNAs were selected using the… More >

  • Open Access

    REVIEW

    Research advancements in nanoparticles and cell-based drug delivery systems for the targeted killing of cancer cells

    MERYEM A. ABDESSALEM, SIRIN A. ADHAM*

    Oncology Research, Vol.33, No.1, pp. 27-44, 2025, DOI:10.32604/or.2024.056955 - 20 December 2024

    Abstract Nanotechnology in cancer therapy has significantly advanced treatment precision, effectiveness, and safety, improving patient outcomes and personalized care. Engineered smart nanoparticles and cell-based therapies are designed to target tumor cells, precisely sensing the tumor microenvironment (TME) and sparing normal cells. These nanoparticles enhance drug accumulation in tumors by solubilizing insoluble compounds or preventing their degradation, and they can also overcome therapy resistance and deliver multiple drugs simultaneously. Despite these benefits, challenges remain in patient-specific responses and regulatory approvals for cell-based or nanoparticle therapies. Cell-based drug delivery systems (DDSs) that primarily utilize the immune-recognition principle between… More > Graphic Abstract

    Research advancements in nanoparticles and cell-based drug delivery systems for the targeted killing of cancer cells

  • Open Access

    ARTICLE

    Deep learning identification of novel autophagic protein-protein interactions and experimental validation of Beclin 2-Ubiquilin 1 axis in triple-negative breast cancer

    XIANG LI1,#, WENKE JIN2,#, LIFENG WU2, HUAN WANG1, XIN XIE1, WEI HUANG1,*, BO LIU2,*

    Oncology Research, Vol.33, No.1, pp. 67-81, 2025, DOI:10.32604/or.2024.055921 - 20 December 2024

    Abstract Background: Triple-negative breast cancer (TNBC), characterized by its lack of traditional hormone receptors and HER2, presents a significant challenge in oncology due to its poor response to conventional therapies. Autophagy is an important process for maintaining cellular homeostasis, and there are currently autophagy biomarkers that play an effective role in the clinical treatment of tumors. In contrast to targeting protein activity, intervention with protein-protein interaction (PPI) can avoid unrelated crosstalk and regulate the autophagy process with minimal interference pathways. Methods: Here, we employed Naive Bayes, Decision Tree, and k-Nearest Neighbors to elucidate the complex PPI… More >

  • Open Access

    ARTICLE

    HNRNPC as a pan-cancer biomarker and therapeutic target involved in tumor progression and immune regulation

    YUEZHOU ZHANG1,#, ZHAO ZHANG2,#, JINXIN DONG1, CHANGAN LIU1,*

    Oncology Research, Vol.33, No.1, pp. 83-102, 2025, DOI:10.32604/or.2024.055866 - 20 December 2024

    Abstract Background: Aberrant expression of RNA-binding proteins (RBPs) has been linked to a variety of diseases, including hematological disorders, cardiovascular diseases, and multiple types of cancer. Heterogeneous nuclear ribonucleoprotein C (HNRNPC), a member belonging to the heterogeneous nuclear ribonucleoprotein (hnRNP) family, plays a pivotal role in nucleic acid metabolism. Previous studies have underscored the significance of HNRNPC in tumorigenesis; however, its specific role in malignant tumor progression remains inadequately characterized. Methods: We leveraged publicly available databases, including The Cancer Genome Atlas (TCGA), to explore the potential involvement of HNRNPC across various cancers. Additionally, we performed experimental… More > Graphic Abstract

    HNRNPC as a pan-cancer biomarker and therapeutic target involved in tumor progression and immune regulation

  • Open Access

    ARTICLE

    SBL-JP-0004: A promising dual inhibitor of JAK2 and PI3KCD against gastric cancer

    HASSAN M. OTIFI*

    Oncology Research, Vol.33, No.1, pp. 235-243, 2025, DOI:10.32604/or.2024.055677 - 20 December 2024

    Abstract Background: Gastric cancer (GC) remains a global health burden and is often characterized by heterogeneous molecular profiles and resistance to conventional therapies. The phosphoinositide 3-kinase and PI3K and Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathways play pivotal roles in GC progression, making them attractive targets for therapeutic interventions. Methods: This study applied a computational and molecular dynamics simulation approach to identify and characterize SBL-JP-0004 as a potential dual inhibitor of JAK2 and PI3KCD kinases. KATOIII and SNU-5 GC cells were used for in vitro evaluation. Results: SBL-JP-0004 exhibited a robust binding affinity for… More >

  • Open Access

    ARTICLE

    CAF-derived exosome-miR-3124-5p promotes malignant biological processes in NSCLC via the TOLLIP/TLR4-MyD88-NF-κB pathway

    TAO SUN1,2, QINGHUA SONG3, HUA LIU1,*

    Oncology Research, Vol.33, No.1, pp. 133-148, 2025, DOI:10.32604/or.2024.054141 - 20 December 2024

    Abstract Background: Lung cancer is a life-threatening disease that occurs worldwide, but is especially common in China. The crucial role of the tumour microenvironment (TME) in non-small cell lung cancer (NSCLC) has attracted recent attention. Cancer-associated fibroblasts (CAFs) are the main factors that contribute to the TME function, and CAF exosomes are closely linked to NSCLC. Methods: The expression levels of miR-3124-5p and Toll-interacting protein (TOLLIP) were analysed by bioinformatics prediction combined with RT-qPCR/Western Blot detection. Fibroblasts were isolated and identified from clinical NSCLC tissues. Transmission electron microscopy and Western Blot were used to identify exosomes… More >

  • Open Access

    REVIEW

    Three-dimensional models: from cell culture to Patient-Derived Organoid and its application to future liposarcoma research

    SAYUMI TAHARA1, SYDNEY RENTSCH1, FERNANDA COSTAS CASAL DE FARIA1, PATRICIA SARCHET1, ROMA KARNA1, FEDERICA CALORE2,*, RAPHAEL E. POLLOCK1

    Oncology Research, Vol.33, No.1, pp. 1-13, 2025, DOI:10.32604/or.2024.053635 - 20 December 2024

    Abstract Liposarcoma is one of the most common soft tissue sarcomas, however, its occurrence rate is still rare compared to other cancers. Due to its rarity, in vitro experiments are an essential approach to elucidate liposarcoma pathobiology. Conventional cell culture-based research (2D cell culture) is still playing a pivotal role, while several shortcomings have been recently under discussion. In vivo, mouse models are usually adopted for pre-clinical analyses with expectations to overcome the issues of 2D cell culture. However, they do not fully recapitulate human dedifferentiated liposarcoma (DDLPS) characteristics. Therefore, three-dimensional (3D) culture systems have been the recent… More >

  • Open Access

    REVIEW

    Engendered nanoparticles for treatment of brain tumors

    SOROUSH SOLEYMANI1, MOHAMMAD DOROUDIAN2,*, MAHDIEH SOEZI3,4, ALI BELADI5, KIARASH ASGARI2, ASO MOBARAKSHAHI2, ARYANA AGHAEIPOUR2, RONAN MACLOUGHLIN6,7,8,*

    Oncology Research, Vol.33, No.1, pp. 15-26, 2025, DOI:10.32604/or.2024.053069 - 20 December 2024

    Abstract Brain metastasis and primary glioblastoma multiforme represent the most common and lethal malignant brain tumors. Its median survival time is typically less than a year after diagnosis. One of the major challenges in treating these cancers is the efficiency of the transport of drugs to the central nervous system. The blood-brain barrier is cooperating with advanced stages of malignancy. The blood-brain barrier poses a significant challenge to delivering systemic medications to brain tumors. Nanodrug delivery systems have emerged as promising tools for effectively crossing this barrier. Additionally, the development of smart nanoparticles brings new hope More >

  • Open Access

    ARTICLE

    The impact of alpha-fetoprotein (AFP), child-turcotte-pugh (CTP) score and disease staging on the survival of hepatocellular carcinoma (HCC) patients: a retrospective cohort from single oncology center

    NASSER MULLA1,*, YOUSEF KATIB2, ASIM M. ALMUGHAMSI3, DUAA S. ALKHAYAT1, MOHAMED MOSAAD1,4, SAMIR T. ALFOTIH5, RAWAN ALAOFI6

    Oncology Research, Vol.33, No.1, pp. 149-160, 2025, DOI:10.32604/or.2024.050903 - 20 December 2024

    Abstract Background: Hepatocellular carcinoma (HCC) is the most common cause of cancer-related death in Saudi Arabia. Our study aimed to investigate the patterns of HCC and the effect of TNM staging, Alfa-fetoprotein (AFP), and Child-Turcotte Pugh (CTP) on patients’ overall survival (OS). Methods: A retrospective analysis was conducted on 43 HCC patients at a single oncology center in Saudi Arabia from 2015 to 2020. All patients had to fulfill one of the following criteria: (a) a liver lesion reported as definitive HCC on dynamic imaging and/or (b) a biopsy-confirmed diagnosis. Results: The mean patient age of all… More >

  • Open Access

    ARTICLE

    Genetic signatures of ERCC1 and ERCC2 expression, along with SNPs variants, unveil favorable prognosis in SCLC patients undergoing platinum-based chemotherapy

    ENRICO CALIMAN1,2, SARA FANCELLI1,2, FEDERICO SCOLARI3, ADRIANO PASQUI4, CLARA MANNESCHI4, DANIELE LAVACCHI1, FRANCESCA MAZZONI4, FRANCESCA GENSINI5, VALERIA PASINI6, CAMILLA EVA COMIN2,7, LUCA VOLTOLINI2,8, SERENA PILLOZZI1,2,*, LORENZO ANTONUZZO1,2,4

    Oncology Research, Vol.33, No.1, pp. 45-55, 2025, DOI:10.32604/or.2024.050161 - 20 December 2024

    Abstract Background: Platinum chemotherapy (CT) remains the backbone of systemic therapy for patients with small-cell lung cancer (SCLC). The nucleotide excision repair (NER) pathway plays a central role in the repair of the DNA damage exerted by platinum agents. Alteration in this repair mechanism may affect patients’ survival. Materials and Methods: We conducted a retrospective analysis of data from 38 patients with extensive disease (ED)-SCLC who underwent platinum-CT at the Clinical Oncology Unit, Careggi University Hospital, Florence (Italy), from 2015 to 2020. mRNA expression analysis and single nucleotide polymorphism (SNP) characterization of three NER pathway genes—namely ERCC1, ERCC2,… More >

Displaying 1-10 on page 1 of 24762. Per Page